Skip to main content

RT @doctorRBC: 2nd Plenary Session! Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study) I

Nov 13, 2022 11:51 am
Social Author Name
Robert B Chao, MD
Tweet Content
2nd Plenary Session! Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study) Improvement of ESSDAI, salivary flow and pathologically elevated Ig's Abs#1113 @RheumNow #ACR22 https://t.co/vdgxBPe6qd
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×